Update of survival and cost of metastatic melanoma with new drugs: Estimations from the MelBase cohort
M. Kandel(Institut Gustave Roussy), Isabelle Borget(Université Paris-Sud), M.‐T. Leccia(Centre Hospitalier Universitaire de Grenoble), Célèste Lebbé(Inserm), S. Dalac(CHU Dijon Bourgogne), Jean‐Philippe Arnault(Centre Hospitalier Universitaire Amiens-Picardie), Thierry Lesimple, Philippe Saïag(Université de Versailles Saint-Quentin-en-Yvelines), F. Granel‐Brocard(Centre Hospitalier Régional et Universitaire de Nancy), A. Dupuy(Hôpital Pontchaillou), Federico Rotolo(Inserm), F. Brunet‐Possenti(Université Claude Bernard Lyon 1), E. Maubec(Délégation Paris 7), A. Ballon(Inserm), F. Aubin, Délphine Legoupil(Centre Hospitalier Régional Universitaire de Brest), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), J.‐P. Lacour(Institut Gustave Roussy), Jean‐Jacques Grob, Stefan Michiels(Institut Gustave Roussy), B. Guillot(Université de Montpellier), Clara Allayous(Inserm), Stéphane Dalle(Mount Sinai Hospital), Laurent Mortier, Brigitte Dréno(Inserm), P Stoebner, M. Beylot‐Barry
Cited by 38
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k